| Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines P Nicolosi, E Ledet, S Yang, S Michalski, B Freschi, E O’Leary, ED Esplin, ... JAMA oncology 5 (4), 523-528, 2019 | 325 | 2019 |
| Yield and utility of germline testing following tumor sequencing in patients with cancer SE Lincoln, RL Nussbaum, AW Kurian, SM Nielsen, K Das, S Michalski, ... JAMA Network Open 3 (10), e2019452-e2019452, 2020 | 86 | 2020 |
| Underdiagnosis of hereditary breast and ovarian cancer in Medicare patients: genetic testing criteria miss the mark S Yang, JE Axilbund, E O’Leary, ST Michalski, R Evans, SE Lincoln, ... Annals of surgical oncology 25, 2925-2931, 2018 | 82 | 2018 |
| Expanded gene panel use for women with breast cancer: identification and intervention beyond breast cancer risk E O’leary, D Iacoboni, J Holle, ST Michalski, ED Esplin, S Yang, K Ouyang Annals of surgical oncology 24, 3060-3066, 2017 | 68 | 2017 |
| Costs and consequences of comprehensive stillbirth assessment ST Michalski, J Porter, RM Pauli American journal of obstetrics and gynecology 186 (5), 1027-1034, 2002 | 66 | 2002 |
| Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer DF Clark, ST Michalski, R Tondon, B Nehoray, J Ebrahimzadeh, ... Genetics in Medicine 22 (5), 840-846, 2020 | 41 | 2020 |
| Clinical cohort analysis of germline EGFR T790M demonstrates penetrance across ethnicities and races, sexes, and ages DK Berry, X Wang, ST Michalski, HC Kang, S Yang, BC Creelan, ... JCO Precision Oncology 4, 2020 | 16 | 2020 |
| Landscape of pathogenic germline variants in patients with lung cancer. S Sorscher, J LoPiccolo, E Chen, B Heald, ST Michalski, SM Nielsen, ... Journal of Clinical Oncology 40 (36_suppl), 388570-388570, 2022 | 11 | 2022 |
| Germline pathogenic variant prevalence among Latin American and US Hispanic individuals undergoing testing for hereditary breast and ovarian cancer: a cross-sectional study CA Ossa Gomez, MI Achatz, M Hurtado, MC Sanabria-Salas, ... JCO Global Oncology 8, e2200104, 2022 | 10 | 2022 |
| Correction: Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria K Nykamp, M Anderson, M Powers, J Garcia, B Herrera, YY Ho, ... Genet Med 22 (1), 240, 2020 | 10 | 2020 |
| Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer B Heald, S Mokhtary, SM Nielsen, S Rojahn, S Yang, ST Michalski, ... Gynecologic oncology 166 (2), 344-350, 2022 | 8 | 2022 |
| Underdiagnosis of hereditary colorectal cancers among medicare patients: genetic testing criteria for lynch syndrome miss the mark C Muller, SM Nielsen, KE Hatchell, S Yang, ST Michalski, B Hamlington, ... JCO Precision Oncology 5, 1103-1111, 2021 | 8 | 2021 |
| Germline hemizygous deletion of CDKN2A–CDKN2B locus in a patient presenting with Li–Fraumeni syndrome SH Chan, WK Lim, ST Michalski, JQ Lim, NDB Ishak, M Met-Domestici, ... NPJ Genomic Medicine 1 (1), 1-6, 2016 | 7 | 2016 |
| Yield and utility of germline testing following tumor sequencing in patients with cancer. JAMA Netw Open. 2020; 3 (10): e2019452 SE Lincoln, RL Nussbaum, AW Kurian, SM Nielsen, K Das, S Michalski Přejít k původnímu zdroji... Přejít na PubMed, 2020 | 6 | 2020 |
| Need for re-evaluation of current guidelines based on results from germline genetic testing in prostate cancer. PLW Nicolosi, ST Michalski, B Freschi, E O'Leary, R Quintana, I Wilson, ... Journal of Clinical Oncology 35 (15_suppl), 5009-5009, 2017 | 6 | 2017 |
| Rate of pathogenic germline variants in patients with lung cancer S Sorscher, J LoPiccolo, B Heald, E Chen, SL Bristow, ST Michalski, ... JCO Precision Oncology 7, e2300190, 2023 | 5 | 2023 |
| Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients W Espinel, M Champine, H Hampel, J Jeter, K Sweet, R Pilarski, ... Cancers 14 (10), 2426, 2022 | 5 | 2022 |
| Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility. ST Michalski, DE Pineda Alvarez, M Russell, S Yang, G Sonpavde, ... Journal of Clinical Oncology 37 (15_suppl), 1580-1580, 2019 | 1 | 2019 |
| Germline DNA repair mutations in men with prostate cancer are less frequent in African Americans as compared with Caucasians. PLW Nicolosi, E Ledet, S Yang, ST Michalski, J Vu, AO Sartor Journal of Clinical Oncology 37 (7_suppl), 258-258, 2019 | 1 | 2019 |
| Landscape of germline mutations in hepatobiliary carcinoma: Unrealized risk, untapped clinical trial opportunities. J Samadder, M Rupp, S Yang, ST Michalski, SE Lincoln, RL Nussbaum, ... Journal of Clinical Oncology 37 (4_suppl), 236-236, 2019 | 1 | 2019 |
